FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912631401> ?p ?o ?g. }

• W2912631401 endingPage "345" @default.
• W2912631401 startingPage "337" @default.
• W2912631401 abstract "The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival. Here we analyze a group of patients with GBM who received bevacizumab treatment at recurrence and are stratified according to tumor molecular and genomic profile (TCGA classification), with the goal of identifying molecular predictors of the response to bevacizumab. We performed a retrospective review of patients with a diagnosis of glioblastoma who were treated with bevacizumab in the recurrent setting at our hospital, from 2006 to 2014. Treatment was discontinued by the treating neuro-oncologists, based on clinical and radiographic criteria. Pre- and post-treatment imaging and genomic subtype were available on 80 patients. We analyzed time on bevacizumab and time to progression. EGFR gene amplification was determined by FISH. Patients with classical tumors had a significantly shorter time on bevacizumab than mesenchymal, and proneural patients (2.7 vs. 5.1 vs. 6.4 and 6.0 months respectively, p = 0.011). Classical subtype and EGFR gene amplification were significantly associated with a shorter time to progression both in univariate (p < 0.001 and p = 0.007, respectively) and multivariate analysis (both p = 0.010). EGFR gene amplification and classical subtype by TCGA analysis are associated with significantly shorter time to progression for patients with recurrent GBM when treated with bevacizumab. These findings can have a significant impact on decision-making and should be further validated prospectively." @default.
• W2912631401 created "2019-02-21" @default.
• W2912631401 creator A5002965160 @default.
• W2912631401 creator A5024476694 @default.
• W2912631401 creator A5039486054 @default.
• W2912631401 creator A5048552055 @default.
• W2912631401 creator A5050137917 @default.
• W2912631401 creator A5081823120 @default.
• W2912631401 creator A5087562855 @default.
• W2912631401 creator A5088235927 @default.
• W2912631401 date "2019-01-24" @default.
• W2912631401 modified "2023-10-15" @default.
• W2912631401 title "EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma" @default.
• W2912631401 cites W1614604802 @default.
• W2912631401 cites W1969328947 @default.
• W2912631401 cites W1979714353 @default.
• W2912631401 cites W1987668448 @default.
• W2912631401 cites W2012748193 @default.
• W2912631401 cites W2020820485 @default.
• W2912631401 cites W2036117141 @default.
• W2912631401 cites W2090785782 @default.
• W2912631401 cites W2096226098 @default.
• W2912631401 cites W2109816625 @default.
• W2912631401 cites W2113942802 @default.
• W2912631401 cites W2124736921 @default.
• W2912631401 cites W2129366802 @default.
• W2912631401 cites W2132697290 @default.
• W2912631401 cites W2134807618 @default.
• W2912631401 cites W2144487043 @default.
• W2912631401 cites W2156330848 @default.
• W2912631401 cites W2160560911 @default.
• W2912631401 cites W2161289668 @default.
• W2912631401 cites W2167923186 @default.
• W2912631401 cites W2232686527 @default.
• W2912631401 cites W2276391444 @default.
• W2912631401 cites W2293809486 @default.
• W2912631401 cites W2366536035 @default.
• W2912631401 cites W2401025370 @default.
• W2912631401 cites W2405099481 @default.
• W2912631401 cites W2544276355 @default.
• W2912631401 cites W2604902526 @default.
• W2912631401 cites W2785630001 @default.
• W2912631401 doi "https://doi.org/10.1007/s11060-019-03102-5" @default.
• W2912631401 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6752204" @default.
• W2912631401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30680510" @default.
• W2912631401 hasPublicationYear "2019" @default.
• W2912631401 type Work @default.
• W2912631401 sameAs 2912631401 @default.
• W2912631401 citedByCount "27" @default.
• W2912631401 countsByYear W29126314012019 @default.
• W2912631401 countsByYear W29126314012020 @default.
• W2912631401 countsByYear W29126314012021 @default.
• W2912631401 countsByYear W29126314012022 @default.
• W2912631401 countsByYear W29126314012023 @default.
• W2912631401 crossrefType "journal-article" @default.
• W2912631401 hasAuthorship W2912631401A5002965160 @default.
• W2912631401 hasAuthorship W2912631401A5024476694 @default.
• W2912631401 hasAuthorship W2912631401A5039486054 @default.
• W2912631401 hasAuthorship W2912631401A5048552055 @default.
• W2912631401 hasAuthorship W2912631401A5050137917 @default.
• W2912631401 hasAuthorship W2912631401A5081823120 @default.
• W2912631401 hasAuthorship W2912631401A5087562855 @default.
• W2912631401 hasAuthorship W2912631401A5088235927 @default.
• W2912631401 hasBestOaLocation W29126314012 @default.
• W2912631401 hasConcept C121608353 @default.
• W2912631401 hasConcept C126322002 @default.
• W2912631401 hasConcept C143998085 @default.
• W2912631401 hasConcept C144301174 @default.
• W2912631401 hasConcept C167135981 @default.
• W2912631401 hasConcept C204232928 @default.
• W2912631401 hasConcept C2776194525 @default.
• W2912631401 hasConcept C2776694085 @default.
• W2912631401 hasConcept C2777802072 @default.
• W2912631401 hasConcept C2779256057 @default.
• W2912631401 hasConcept C2780739268 @default.
• W2912631401 hasConcept C38180746 @default.
• W2912631401 hasConcept C502942594 @default.
• W2912631401 hasConcept C71924100 @default.
• W2912631401 hasConceptScore W2912631401C121608353 @default.
• W2912631401 hasConceptScore W2912631401C126322002 @default.
• W2912631401 hasConceptScore W2912631401C143998085 @default.
• W2912631401 hasConceptScore W2912631401C144301174 @default.
• W2912631401 hasConceptScore W2912631401C167135981 @default.
• W2912631401 hasConceptScore W2912631401C204232928 @default.
• W2912631401 hasConceptScore W2912631401C2776194525 @default.
• W2912631401 hasConceptScore W2912631401C2776694085 @default.
• W2912631401 hasConceptScore W2912631401C2777802072 @default.
• W2912631401 hasConceptScore W2912631401C2779256057 @default.
• W2912631401 hasConceptScore W2912631401C2780739268 @default.
• W2912631401 hasConceptScore W2912631401C38180746 @default.
• W2912631401 hasConceptScore W2912631401C502942594 @default.
• W2912631401 hasConceptScore W2912631401C71924100 @default.
• W2912631401 hasIssue "2" @default.
• W2912631401 hasLocation W29126314011 @default.
• W2912631401 hasLocation W29126314012 @default.
• W2912631401 hasLocation W29126314013 @default.
• W2912631401 hasLocation W29126314014 @default.
• W2912631401 hasOpenAccess W2912631401 @default.

• next